Plain-English translation of NCT05829733 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing Synolis VA 80/160, a special fluid injected directly into the hip joint to help reduce osteoarthritis pain. The study will follow 70 people over 6 months to see whether this single injection provides lasting relief and is safe. Researchers want to understand whether this treatment works better than current options for people whose hip pain hasn't improved with regular pain relievers.
Hip osteoarthritis can cause significant pain that doesn't always respond well to pills or over-the-counter pain relievers. This medication offers a different approach—delivering treatment directly to the affected joint—and this trial will determine whether it can safely and effectively reduce symptoms that haven't improved with standard care.
You likely qualify if…
You likely don't qualify if…
You will receive a single guided injection directly into your hip joint at a clinic visit. The doctor will use imaging to ensure accurate placement of the medication. You will then return for follow-up visits over the next 6 months so researchers can check how well the treatment is working, measure your pain levels, and watch for any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
France
Sponsor
Aptissen SA
Enrollment target
~70 participants
Started
May 2024
Primary completion
April 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eduard Vidovic, MD
Aptissen SA
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.